Peter Kelleher

Jul 6, 2023 | nature.com | Eleanor J. Barnes |Carl S. Goodyear |Michelle Willicombe |Stefan Siebert |John A Snowden |Peter Kelleher | +3 more

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml−1).